• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biocorrx Inc (OP: BICX )

    0.4100 UNCHANGED
    Last Price Updated: 3:35 PM EST, Jan 6, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.4100
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.4100
    Today's Range 0.4100 - 0.4100
    52wk Range 0.2820 - 1.500
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioCorRx Reports Business Update for the Second Quarter of 2024
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Intellectual Property
    Exposures Intellectual Property
    BioCorRx Reports Business Update for the First Quarter of 2024
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Topics Death Intellectual Property
    Exposures Death Intellectual Property

    Performance

    YTD
    N/A
    N/A
    1 Month
    -18.00%
    -18.00%
    3 Month
    +36.67%
    +36.67%
    6 Month
    -16.33%
    -16.33%
    1 Year
    -41.43%
    -41.43%

    More News

    Read More
    BioCorRx Reports Business Update for the First Quarter of 2024
    Via TheNewswire.com
    Topics Death Intellectual Property
    Exposures Death Intellectual Property
    BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
    Via NewMediaWire
    Topics Intellectual Property
    Exposures Intellectual Property
    BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
    Via TheNewswire.com
    Topics Intellectual Property
    Exposures Intellectual Property
    BioCorRx Reports Business Update for 2023
    Via NewMediaWire
    Topics Death
    Exposures Death
    BioCorRx Reports Business Update for 2023
    Via TheNewswire.com
    Topics Death
    Exposures Death
    BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
    Via NewMediaWire
    BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
    Via TheNewswire.com
    Topics Death
    Exposures Death
    BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
    Via NewMediaWire
    BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
    Via TheNewswire.com
    Collective Audience And 3 Other Stocks Under $1 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
    Via NewMediaWire
    BioCorRx Reports Business Update for the Third Quarter of 2023
    Via NewMediaWire
    Topics Death
    Exposures Death
    BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
    Via NewMediaWire
    Exposures Product Safety
    BioCorRx Reports Business Update for the Second Quarter of 2023
    Via NewMediaWire
    Exposures Product Safety
    BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
    Via NewMediaWire
    Topics Death
    Exposures Death Product Safety
    Rezolute And 2 Other Penny Stocks Insiders Are Aggressively Buying
    Via Benzinga
    BioCorRx Provides Business Update for the First Quarter of 2023
    Via NewMediaWire
    BioCorRx Provides Business Update for 2022
    Via NewMediaWire
    BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
    Via NewMediaWire
    BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
    Via NewMediaWire
    Exposures Product Safety
    BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
    Via NewMediaWire
    BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
    Via NewMediaWire
    BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
    Via NewMediaWire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.